Products
RainDance Technologies ADMESeq™ Research Screening Panel*
Raindance Technologies and Ambry Genetics have developed a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The RainDance ADMESeq™ Research Screening Panel enables researchers to simultaneously interrogate the coding regions of 242 known pharmacogenetic genes, in a single assay. Researchers can now cost-effectively apply next-generation sequencing (NGS) technology more routinely to detect known and novel mutations leading to adverse drug reactions and events.
In recent years, the biotechnology and pharmaceutical industries have been genotyping ADME genes earlier in the drug development pipeline, to help reduce the significant costs associated with failed drug trials and hospitalizations due to adverse events. However, current genotyping tools interrogate only a small number of known biomarkers and lack the genomic coverage to detect important variants across a wide range of genes implicated with ADME.
Comprehensive Content
The new ADMESeq Research Screening Panel provides scientists with the capacity to perform sequence analysis of entire coding regions of 242 key drug metabolism-linked genes, including 44 membrane transporters, 42 VIP genes from the PharmGKB (Pharmacogenomics Knowledge Base), and 86 FDA-identified pharmacogenomics biomarker genes.
The RainDance ADMESeq™ Research Screening Panel Advantages
- Sequence 242 ADME genes at the same time
- Detect genetically rare variants, not seen with genotyping
- Optimize sequencer efficiency and increase sample throughput
- Apply next-generation sequencing technology more routinely
- Accelerate time to results and simplify workflow
*The RainDance ADMESeq™ Screening Panel is for Research Use Only. Not for use in diagnostic procedures.
“We are very pleased to be working closely with RainDance and to deliver this innovative and first-of-its-kind ADME sequencing service. We are confident that our pharmaceutical, biotechnology and research customers will be eager to utilize this novel predictive toxicology tool to enhance their drug safety strategies and reduce the costs associated with performing ADME analysis across the many research projects and clinical trials that rely on these critical data.”
Ardy Arianpour, Vice President of Business Development at Ambry Genetics.
Press Release
10/24/2011 – RainDance Technologies and Ambry Genetics Launch Industry's Most Comprehensive DNA Sequencing Panel for ADME Research
